SCHEMBL1640023

SCHEMBL1640023

CCOC(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.73
MAPT P10636 4/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
TSHR P16473 2/20 0.73
NPC1 O15118 3/20 0.70
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
LMNA P02545 3/20 0.66
ALDH1A1 P00352 2/20 0.66
USP2 O75604 2/20 0.66
ALOX15 P16050 1/20 0.66
HSD17B10 Q99714 1/20 0.66
ADRB2 P07550 3/20 0.61
ADRB1 P08588 3/20 0.61
ADRB3 P13945 3/20 0.61
SIRT2 Q8IXJ6 1/20 0.61
SIRT1 Q96EB6 1/20 0.61
SIRT3 Q9NTG7 1/20 0.61
RXFP1 Q9HBX9 1/20 0.61
CYP1A2 P05177 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394052 1.00 RAB9A (0.73) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL1464834 0.90 MAPK1 (0.69) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL2995600 0.88 MAPT (0.67) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL1751226 0.88 MAPT (0.59) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL11691955 0.87 RAB9A (0.62) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL5827808 0.86 SIRT2 (0.64) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL4027801 0.86 RAB9A (0.57) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL20826393 0.86 MAPT (0.64) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL12395553 0.86 MAPT (0.64) RAB9AMAPTL3MBTL1TSHRNPC1
SCHEMBL5046606 0.85 MAPT (0.56) RAB9AMAPTL3MBTL1TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190010427-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY 2019-01-10 US claimed
US-20190010293-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY 2019-01-10 US claimed
CN-114007734-A Method for preparing capsules 宝洁公司 2022-02-01 CN disclosed
CN-113660926-A Capsule 宝洁公司 2021-11-16 CN disclosed
CN-113631695-A Capsule 宝洁公司 2021-11-09 CN disclosed
CN-108699041-B Imidazole derivative having JNK inhibitory activity and use thereof 三进制药株式会社 2021-03-26 CN disclosed
CN-209210679-U A kind of piperonal recyclable device 四川惠泉生物科技有限公司 2019-08-06 CN disclosed
US-20190010293-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY 2019-01-10 US disclosed
US-20190010427-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY 2019-01-10 US disclosed
CN-106999973-A System and method for discharging edible material 阿甘芳香和精细化工有限公司 2017-08-01 CN disclosed
US-20110105378-A1 ENCAPSULATES SMETS JOHAN 2011-05-05 US disclosed
US-20030176481-A1 Novel imidazole derivatives with anti-inflammatory activity J. URIACH & CIA S.A. (ES) 2003-09-18 US disclosed
US-6620825-B1 1,3-Azole compound substituted by pyridyl; administering as antiasthmatic, antiinflammatory or antiallergen agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-16 US disclosed
EP-1270559-A1 NOVEL IMIDAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY J. URIACH & CIA. S.A. (ES) 2003-01-02 EP disclosed
US-6436966-B1 Adenosine A3 receptor antagonists TAKEDA CHEMICAL IND., LTD. (JP) 2002-08-20 US disclosed
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP disclosed
EP-1027050-A2 ADENOSINE A3 RECEPTOR ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2000-08-16 EP disclosed
WO-1999021555-A2 ADENOSINE A3 RECEPTOR ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-05-06 WO disclosed
US-4058607-A DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES AIRWICK INDUSTRIES, INC. (US) 1977-11-15 US disclosed
US-3962415-A Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer AIRWICK INDUSTRIES, INC. (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176481-A1 Novel imidazole derivatives with anti-inflammatory activity IL1B, IL1A, MIF RAB9A 2262/4885MAPT 2320/4885L3MBTL1 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.